VOGX
Vogenx, Inc.
Price Chart
Latest Quote
$19.16
+1.82 (+10.50%)
Current Price
| Previous Close | $17.34 |
| Open | $17.18 |
| Day High | $20.75 |
| Day Low | $17.18 |
| Volume | 75,126 |
Stock Information
| Shares Outstanding | 14.86M |
| Total Debt | $868K |
| Cash Equivalents | $193K |
| Net Income | $-1.65M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $284.62M |
| EPS (TTM) | $-0.22 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $285.30M |
| Income | $-1.65M |
| Book/sh | $-0.34 |
| Cash/sh | $0.01 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 0.06 |
| Current Ratio | 0.44 |
Returns & Margins
Ownership
| Insider Ownership | 4.74% |
| Institutional Ownership | 13.48% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -56.69 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $55.00 |
Technical Indicators
| SMA20 | $17.72 |
| SMA50 | $24.83 |
| RSI | 59.89 |
| ATR | 2.7486 |
| Shares Float | 9.81M |
| Short Ratio | 0.18 |
| Rel Volume | 0.79 |
Performance History
| Week | +2.19% |
| Month | -12.91% |
| YTD | +47.38% |
| 10 Years | +47.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $19.16 | 75,100 |
| 2026-10-26 | $17.34 | 106,000 |
| 2026-10-23 | $17.45 | 64,500 |
| 2026-10-22 | $19.08 | 91,000 |
| 2026-10-21 | $20.39 | 84,300 |
| 2026-10-20 | $18.75 | 71,000 |
| 2026-10-19 | $15.92 | 86,900 |
| 2026-10-16 | $14.53 | 84,600 |
| 2026-10-15 | $16.05 | 186,600 |
| 2026-10-14 | $16.10 | 94,200 |
| 2026-10-13 | $16.76 | 98,700 |
| 2026-10-12 | $17.14 | 87,700 |
| 2026-10-09 | $17.56 | 77,200 |
| 2026-10-08 | $17.49 | 142,500 |
| 2026-10-07 | $16.16 | 237,900 |
| 2026-10-06 | $16.39 | 27,100 |
| 2026-10-05 | $17.15 | 60,900 |
| 2026-10-02 | $18.23 | 55,500 |
| 2026-10-01 | $20.06 | 94,600 |
| 2026-09-30 | $22.79 | 79,200 |
| 2026-09-29 | $24.32 | 137,900 |
| 2026-09-28 | $22.00 | 136,100 |
About Vogenx, Inc.
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
đ° Latest News
No news articles available at the moment. Check back later for updates on VOGX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $1,439,118 | $2,300,834 |
| Other Income Expense | $-12,516 | $58,030 |
| Other Non Operating Income Expenses | $-66,300 | - |
| Net Non Operating Interest Income Expense | $6,031 | $39,213 |
| Operating Expense | $1,439,118 | $2,300,834 |
| General And Administrative Expense | $867,153 | $984,309 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-1,445,603 | $-2,203,591 |
| Net Interest Income | $6,031 | $39,213 |
| Interest Income | $6,031 | $39,213 |
| Normalized Income | $-1,499,387 | $-2,261,621 |
| Net Income From Continuing And Discontinued Operation | $-1,445,603 | $-2,203,591 |
| Net Income Common Stockholders | $-1,445,603 | $-2,203,591 |
| Net Income | $-1,445,603 | $-2,203,591 |
| Net Income Including Noncontrolling Interests | $-1,445,603 | $-2,203,591 |
| Net Income Continuous Operations | $-1,445,603 | $-2,203,591 |
| Pretax Income | $-1,445,603 | $-2,203,591 |
| Interest Income Non Operating | $6,031 | $39,213 |
| Operating Income | $-1,439,118 | $-2,300,834 |
| Per Share | ||
| Diluted EPS | - | $-0.29 |
| Basic EPS | - | $-0.29 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,492,902 | $-2,358,864 |
| Total Unusual Items | $53,784 | $58,030 |
| Total Unusual Items Excluding Goodwill | $53,784 | $58,030 |
| EBITDA (Bullshit earnings) | $-1,439,118 | $-2,300,834 |
| EBIT | $-1,439,118 | $-2,300,834 |
| Diluted Average Shares | $7,667,587 | $7,667,587 |
| Basic Average Shares | $7,667,587 | $7,667,587 |
| Diluted NI Availto Com Stockholders | $-1,445,603 | $-2,203,591 |
| Gain On Sale Of Security | $53,784 | $58,030 |
| Research And Development | $571,965 | $1,316,525 |
| Selling General And Administration | $867,153 | $984,309 |
| Other Gand A | $867,153 | $984,309 |
Fetched: 2026-10-27
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-919,235 | $509,584 |
| Total Assets | $681,170 | $970,398 |
| Total Non Current Assets | $0 | $0 |
| Current Assets | $681,170 | $970,398 |
| Current Deferred Assets | $63,363 | - |
| Prepaid Assets | $16,797 | $7,475 |
| Cash Cash Equivalents And Short Term Investments | $601,010 | $962,923 |
| Cash And Cash Equivalents | $601,010 | $962,923 |
| Debt | ||
| Net Debt | $215,290 | - |
| Total Debt | $816,300 | - |
| Current Debt And Capital Lease Obligation | $816,300 | - |
| Current Debt | $816,300 | - |
| Other Current Borrowings | $816,300 | - |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $1,600,405 | $460,814 |
| Total Non Current Liabilities Net Minority Interest | $11,323 | $65,107 |
| Derivative Product Liabilities | $11,323 | $65,107 |
| Current Liabilities | $1,589,082 | $395,707 |
| Payables And Accrued Expenses | $486,282 | $395,707 |
| Payables | $486,282 | $395,707 |
| Other Payable | $363,318 | $286,500 |
| Accounts Payable | $62,964 | $109,207 |
| Equity | ||
| Common Stock Equity | $-919,801 | $509,018 |
| Preferred Stock Equity | $566 | $566 |
| Total Equity Gross Minority Interest | $-919,235 | $509,584 |
| Stockholders Equity | $-919,235 | $509,584 |
| Retained Earnings | $-10,841,670 | $-9,396,067 |
| Other | ||
| Ordinary Shares Number | $13,917,587 | $13,917,587 |
| Share Issued | $13,917,587 | $13,917,587 |
| Tangible Book Value | $-919,801 | $509,018 |
| Invested Capital | $-103,501 | $509,018 |
| Working Capital | $-907,912 | $574,691 |
| Total Capitalization | $-919,235 | $509,584 |
| Additional Paid In Capital | $9,920,290 | $9,903,506 |
| Capital Stock | $2,145 | $2,145 |
| Common Stock | $1,579 | $1,579 |
| Preferred Stock | $566 | $566 |
| Pensionand Other Post Retirement Benefit Plans Current | $286,500 | - |
| Dueto Related Parties Current | $423,318 | $286,500 |
Fetched: 2026-10-27
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-1,111,913 | $-2,341,372 |
| Operating Activities | ||
| Operating Cash Flow | $-1,111,913 | $-2,341,372 |
| Cash Flow From Continuing Operating Activities | $-1,111,913 | $-2,341,372 |
| Operating Gains Losses | $-53,784 | $-58,030 |
| Financing Activities | ||
| Financing Cash Flow | $750,000 | $0 |
| Cash Flow From Continuing Financing Activities | $750,000 | $0 |
| Other | ||
| Issuance Of Debt | $750,000 | $0 |
| End Cash Position | $601,010 | $962,923 |
| Beginning Cash Position | $962,923 | $3,304,295 |
| Changes In Cash | $-361,913 | $-2,341,372 |
| Net Issuance Payments Of Debt | $750,000 | $0 |
| Net Short Term Debt Issuance | $750,000 | $0 |
| Short Term Debt Issuance | $750,000 | $0 |
| Change In Working Capital | $304,390 | $-167,052 |
| Change In Payables And Accrued Expense | $377,075 | $-239,804 |
| Change In Accrued Expense | $423,318 | $-10,625 |
| Change In Payable | $-46,243 | $-229,179 |
| Change In Account Payable | $-46,243 | $-229,179 |
| Change In Prepaid Assets | $-72,685 | $72,752 |
| Other Non Cash Items | $60,500 | - |
| Stock Based Compensation | $16,784 | $87,301 |
| Unrealized Gain Loss On Investment Securities | $5,800 | $0 |
| Gain Loss On Investment Securities | $-53,784 | $-58,030 |
| Net Income From Continuing Operations | $-1,445,603 | $-2,203,591 |
Fetched: 2026-10-27